CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|January 1, 2006
First-time generic approvals
Hydromorphone tablets 2, 4, and 8 mg (equiv to Dilaudid tablets)
Advertisement
Hydromorphone tablets 2, 4, and 8 mg (equiv to Dilaudid tablets)
KV PHARMACEUTICAL
Azithromycin tablets 250, 500, and 600 mg (equiv to Zithromax tablets)
TEVA, SANDOZ
Cefprozil tablets 250 and 500 mg (equiv to Cefzil tablets)
SANDOZ
Promethazine tablets 12.5, 25, and 50 mg (equiv to Phenergan tablets)
ZYDUS
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tariffs on patented drugs now apply to all branded drugmakers
2
A head-to-head phase 3b comparison of bimekizumab with risankizumab in active psoriatic arthritis: Written recap
3
Fewer than 1 in 5 young patients with first-episode psychosis adhere to antipsychotics
4
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
5